Clinical trial Recruiting at 7 sites Observational Ages 18 and up

Best time for reperfusion in acute pulmonary embolism

Official title: Optimal Time for Reperfusion in Acute Pulmonary Embolism

Run by Azienda ULSS 8 Berica · NCT07436702 · Data updated 2026-11-12

This study will test whether performing reperfusion (systemic thrombolysis or catheter‑directed therapy) earlier improves survival and reduces complications in adults with high‑risk or intermediate‑high‑risk pulmonary embolism.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment500 (estimated)
SponsorAzienda ULSS 8 Berica
Academic / other
Locations7 sites (Milan, Milano and 6 other locations)
StatusRecruiting
StartedNovember 25, 2025
Main results expectedOctober 30, 2026
Study endsOctober 30, 2026
Registry record updatedMarch 3, 2026
Trial IDNCT07436702 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) with imaging‑confirmed high‑risk or intermediate‑high‑risk pulmonary embolism who can provide informed consent and are treated at participating centers.

Probably not a fit

Patients with low‑risk PE, chronic stable PE, those who cannot receive reperfusion therapies, or those treated outside participating centers are unlikely to receive direct benefit from this study's findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a national, multicenter, prospective observational study enrolling adults with imaging‑confirmed high‑risk or intermediate‑high‑risk pulmonary embolism at participating Italian centers. Investigators will record timing from symptom onset and hospital admission to reperfusion with systemic thrombolysis or catheter‑directed therapies and track in‑hospital mortality as well as hemorrhagic and cardiovascular complications. Time‑to‑treatment analyses will be used to identify temporal cutoffs associated with better outcomes while accounting for comorbidities and bleeding risk. The goal is to provide evidence on whether a specific reperfusion time window is associated with improved short‑term clinical outcomes.

Why it matters

Potential benefit: If successful, defining an optimal reperfusion time window could increase survival and reduce hemodynamic collapse and bleeding by guiding earlier treatment decisions.

How similar studies have gone: Systemic thrombolysis and catheter‑directed therapies are established for selected high‑risk PE, but prospective, multicenter evidence specifically defining optimal timing is limited and largely untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18 years
* Patients with a diagnosis of intermediate-high or high pulmonary embolism confirmed by computed tomography pulmonary angiography (CTPA), pulmonary angiography, or echocardiography (evidence of a floating thrombus in the right atrium or right ventricle, or proximal visualization of thrombus in the pulmonary artery).
* Classified as high-risk or intermediate-high-risk according to the 2019 European Society of Cardiology guidelines.
* Provision of informed consent for the processing of personal data.

Exclusion Criteria:

* Age \< 18 years
* Patients in whom a diagnosis of acute high-risk or intermediate-high-risk pulmonary embolism has been excluded.
* Inability to provide informed consent.

Where it's running

  • UO Unità di Cure Intensive Cardiologiche e Cardiologia 1, Ospedale Niguarda, Milano
    Milan, Milano, Italy
    Recruiting
  • UOC di Cardiologia, Ospedali Riuniti Padova Sud, Monselice, Italia
    Monselice, Padova, Italy
    Recruiting
  • IRCCS Policlinico San Matteo
    Pavia, Pavia, Italy
    Recruiting
  • UO di Sezione di Medicina Interna e Cardiovascolare, Ospedale Santa Maria della Misericordia, Perugia, Italia
    Perugia, Perugia, Italy
    Recruiting
  • UO di Cardiologia 1, Azienda Ospedaliero Universitaria Pisana, Pisa, Italia
    Pisa, Pisa, Italy
    Recruiting
  • UO di Cardiologia, Azienda Ospedaliera Ordine Mauriziano di Torino
    Torino, Torino, Italy
    Recruiting
Show 1 more location
  • UOC di Cardiologia, Ospedali dell'Ovest Vicentino, Arzignano, IItalia
    Arzignano, Vicenza, Italy
    Recruiting

Study contacts

  • Principal investigator: Claudio Bilato, MD PhD — Department of Cardiology, Azienda AULSS 8 Berica, Arzignano (Vicenza), Italy
  • Study coordinator: Claudio Bilato, MD PhD
  • Email: claudio.bilato@aulss8.veneto.it
  • Phone: +390444479106

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.